CN110279112A - 一种预防三高的绞股蓝酵素及其制备方法 - Google Patents
一种预防三高的绞股蓝酵素及其制备方法 Download PDFInfo
- Publication number
- CN110279112A CN110279112A CN201910591991.8A CN201910591991A CN110279112A CN 110279112 A CN110279112 A CN 110279112A CN 201910591991 A CN201910591991 A CN 201910591991A CN 110279112 A CN110279112 A CN 110279112A
- Authority
- CN
- China
- Prior art keywords
- gynostemma pentaphylla
- ferment
- preparation
- prevention
- cordyceps sinensis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000006509 Gynostemma pentaphyllum Species 0.000 title claims abstract description 25
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 title claims abstract description 25
- 230000002265 prevention Effects 0.000 title claims abstract description 9
- 238000002360 preparation method Methods 0.000 title claims description 8
- 238000000855 fermentation Methods 0.000 title description 2
- 235000021282 Sterculia Nutrition 0.000 claims abstract description 14
- 229940059107 sterculia Drugs 0.000 claims abstract description 14
- 241001248610 Ophiocordyceps sinensis Species 0.000 claims abstract description 13
- 108010011485 Aspartame Proteins 0.000 claims abstract description 9
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 9
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims abstract description 9
- 229960003438 aspartame Drugs 0.000 claims abstract description 9
- 235000010357 aspartame Nutrition 0.000 claims abstract description 9
- 239000000605 aspartame Substances 0.000 claims abstract description 9
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 8
- 235000007516 Chrysanthemum Nutrition 0.000 claims abstract description 7
- 235000012907 honey Nutrition 0.000 claims abstract description 4
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims abstract 3
- 240000001058 Sterculia urens Species 0.000 claims abstract 3
- 239000000284 extract Substances 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 8
- 230000008569 process Effects 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 241000934878 Sterculia Species 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 208000031226 Hyperlipidaemia Diseases 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 241000723353 Chrysanthemum Species 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- 239000004382 Amylase Substances 0.000 description 3
- 102000013142 Amylases Human genes 0.000 description 3
- 108010065511 Amylases Proteins 0.000 description 3
- 235000019418 amylase Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 2
- 241000190633 Cordyceps Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000003345 hyperglycaemic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000002475 laxative effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000009777 vacuum freeze-drying Methods 0.000 description 2
- WDMUXYQIMRDWRC-UHFFFAOYSA-N 2-hydroxy-3,4-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C([N+]([O-])=O)=C1O WDMUXYQIMRDWRC-UHFFFAOYSA-N 0.000 description 1
- 241000303854 Aralia leschenaultii Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241000330899 Hepialus Species 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 241000221775 Hypocreales Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 244000134336 Malus baccata Species 0.000 description 1
- 235000005079 Malus baccata Nutrition 0.000 description 1
- 241000219071 Malvaceae Species 0.000 description 1
- 244000100135 Melanthera biflora Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003471 anti-radiation Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical group C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 1
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229930186669 gynosaponin Natural products 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
一种预防三高的绞股蓝酵素，其特征在于：它是由下列重量百分比成分组成：绞股蓝20‑30％、胖大海10‑20％、灵芝10‑20％、菊花10‑20％、冬虫夏草5‑15％、阿斯巴甜20‑40％、蜂蜜5％‑10％。本发明具有如下优点：方法简单，工序少，工业化、自动化程度高；产品口感好，携带方便，并且具有预防和治疗“三高”的保健功效。
Description
技术领域
本发明涉及保健酵素技术领域，具体涉及一种预防三高的绞股蓝酵素及其制备方法。
背景技术
三高是高血脂、高血压、高血糖的总称。研究表明这三者临床疾病的聚集并非偶然。1988年美国著名内分泌专家Reaven将高血糖中的胰岛素抵抗、高胰岛素血症、糖耐量异常，高血脂中的高甘油三脂血症和高血压统称称为“X综合征”，即现在医学界一般说的代谢综合征，而绞股蓝可以对预防三高起到一定的作用，目前，对于绞股蓝的化学成分和药理作用，已有一些研究：林吉等(林吉，叶其馨，倪晨，等。绞股蓝总甙片治疗高脂血症、血瘀证的实验研究]、海南医学，2005，16(10)：139，90)通过实验动物的高脂血症模型、血瘀症模型，测定总胆固醇、甘油三酯、低密度脂蛋白、高密度脂蛋白、血小板聚集率等指标。结果显示绞股蓝总苷片能明显地降低急性血瘀证模型以及高脂血症的各项指标，提示绞股蓝总苷片可能通过活血祛瘀来降低血脂。魏守蓉等(魏守蓉，薛存宽，何学斌，等。绞股蓝多糖降血糖作用的实验研究]。中国老年学杂志，2005，25(4)：418—420)采用水提醇沉法提取GP，采用3，5一二硝基水杨酸(DNS)比色法观察GP在体外对a一淀粉酶的抑制作用，并且采用正常大鼠和四氧嘧啶高血糖大鼠模型对比，以血糖、糖耐量为指标研究GP的降血糖作用。研究结果表明，GP体外对a一淀粉酶有一定的抑制作用并可降低四氧嘧啶高血糖大鼠的空腹血糖及糖耐量，其降糖机制可能与其刺激胰岛素的释放或促胰岛炎恢复，抑制a-淀粉酶，延缓碳水化合物在小肠的吸收有关。绞股蓝主要有效成份是绞股蓝皂甙、绞股蓝糖甙(多糖)、水溶性氨基酸、黄酮类、多种维生素、微量元素、矿物质等，可治疗高血压、高血脂、高血糖，脂肪肝等症。能够有效地保护心、脑、血管和肝脏，有保肝解毒、降转氨晦、调节免疫和抗诱变，而且在抗衰老、抗疲劳、抗辐射和消除自由基的同时，还能改善神经系统功能、调节内分泌活动。
发明内容
本发明所要解决的技术问题是提供一种预防三高的绞股蓝酵素。
为解决上述技术问题，本发明提供的技术方案为：一种预防三高的绞股蓝酵素，其特征在于：它是由下列重量百分比成分组成：绞股蓝20-30％、胖大海10-20％、灵芝10-20％、菊花10-20％、冬虫夏草5-15％、阿斯巴甜20-40％、蜂蜜5％-10％。
一种预防三高的绞股蓝酵素的制备方法，其特征在于：步骤如下：
(1)、将绞股蓝、胖大海、灵芝、菊花、冬虫夏草洗净，烘干，粉碎，加20-35倍量的纯化水在38℃条件下恒温发酵15天，然后过滤，合并滤液；
(2)、将步骤(1)中的滤液静置后取上清液，浓缩至60℃时测相对密度为1.45-1.55，真空冷冻干燥，得到提取物，过100目筛，得到提取物粉末；
(3)、将阿斯巴甜与步骤(2)中提取物粉末混合均匀后，转移到自动包装机上包装。
优选的，所述阿斯巴甜粒度为过100目筛。
本发明具有如下优点：方法简单，工序少，工业化、自动化程度高；产品口感好，携带方便，并且具有预防和治疗“三高”的保健功效。
具体实施方式
一种预防三高的绞股蓝酵素，其特征在于：它是由下列重量百分比成分组成：绞股蓝20-30％、胖大海10-20％、灵芝10-20％、菊花10-20％、冬虫夏草5-15％、阿斯巴甜20-40％、蜂蜜5％-10％。
其制备方法步骤如下：
(1)、将绞股蓝、胖大海、灵芝、菊花、冬虫夏草洗净，烘干，粉碎，加20-35倍量的纯化水在38℃条件下恒温发酵15天，然后过滤，合并滤液；
(2)、将步骤(1)中的滤液静置后取上清液，浓缩至60℃时测相对密度为1.45-1.55，真空冷冻干燥，得到提取物，过100目筛，得到提取物粉末；
(3)、将阿斯巴甜与步骤(2)中提取物粉末混合均匀后，转移到自动包装机上包装。
所述阿斯巴甜粒度为过100目筛。
绞股蓝，为多年生草质藤木，又称天堂草、福音草、超人参、公罗锅底、遍地生根、七叶胆、五叶参和七叶参等，日本称之甘蔓茶。
灵芝，外形呈伞状，菌盖肾形、半圆形或近圆形，为多孔菌科真菌灵芝的子实体。具有补气安神、止咳平喘的功效，用于眩晕不眠、心悸气短、虚劳咳喘。
冬虫夏草，别名虫草、冬虫草、中华虫草，冬虫夏草功效众多，它是由肉座菌目蛇形虫草科蛇形虫草属的冬虫夏草菌寄生于高山草甸土中的蝠蛾幼虫，使幼虫身躯僵化，并在适宜条件下，夏季由僵虫头端抽生出长棒状的子座而形成，即冬虫夏草菌的子实体与僵虫菌核(幼虫尸体)构成的复合体。主要活性成分是虫草素，冬虫夏草功效主要有调节免疫系统功能、抗肿瘤、抗疲劳、补肺益肾，止血化痰，秘精益气、美白祛黑等多种功效。
胖大海，别名：大海、大海子、大洞果、大发，梧桐科植物胖大海的干燥成熟种子。药理作用如下： 1、抑病毒；现代药理研究表明，胖大海对病毒有较强抑制作用。2、缓泻；启明报道胖大海种子浸出液对兔有缓泻作用。3、镇痛、抑菌；由胖大海、卤地菊与甘草组成的复方对呼吸道常见菌(如金黄色葡萄球菌)的抑制作用较强，对痢疾杆菌引起的结肠粘膜充血、水肿等急性弥漫性纤维蛋白渗出性炎症有缓解作用。4、抗炎；多糖为胖大海抗炎活性成分，但由于不能经肠道吸收，故口服外用效果不佳，腹腔注射效果好。5、免疫；杜力军等报道，胖大海对非特异性免疫没有明显增强作用，但能增强胸腺和脾脏功能。
本发明制备的绞股蓝酵素可以治疗和预防高血压、高血糖、高血脂，也可以根据实际需要制备成固体饮料食用，起到同样的效果，本发明整体配方合理，制备工序少，全程可以实现工业化、自动化操作，制备出的酵素口感佳，同时方便携带，方便日常食用。
以上所述仅为本发明的优选实施例而已，并不用于限制本发明，对于本领域的技术人员来说，本发明可以有各种更改和变化。凡在本发明的精神和原则之内，所作的任何修改、等同替换、改进等，均包含在本发明的保护范围之内。
Claims (3)
1.一种预防三高的绞股蓝酵素，其特征在于：它是由下列重量百分比成分组成：绞股蓝20-30％、胖大海10-20％、灵芝10-20％、菊花10-20％、冬虫夏草5-15％、阿斯巴甜20-40％、蜂蜜5％-10％。
2.一种权利要求1所述的一种预防三高的绞股蓝酵素的制备方法，其特征在于：步骤如下：
(1)、将绞股蓝、胖大海、灵芝、菊花、冬虫夏草洗净，烘干，粉碎，加20-35倍量的纯化水在38℃条件下恒温发酵15天，然后过滤，合并滤液；
(2)、将步骤(1)中的滤液静置后取上清液，浓缩至60℃时测相对密度为1.45-1.55，真空冷冻干燥，得到提取物，过100目筛，得到提取物粉末；
(3)、将阿斯巴甜与步骤(2)中提取物粉末混合均匀后，转移到自动包装机上包装。
3.根据权利要求2所述的一种预防三高的绞股蓝酵素的制备方法，其特征在于：所述阿斯巴甜粒度为过100目筛。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910591991.8A CN110279112A (zh) | 2019-07-02 | 2019-07-02 | 一种预防三高的绞股蓝酵素及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910591991.8A CN110279112A (zh) | 2019-07-02 | 2019-07-02 | 一种预防三高的绞股蓝酵素及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110279112A true CN110279112A (zh) | 2019-09-27 |
Family
ID=68021822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910591991.8A Pending CN110279112A (zh) | 2019-07-02 | 2019-07-02 | 一种预防三高的绞股蓝酵素及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110279112A (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104041809A (zh) * | 2014-06-11 | 2014-09-17 | 沈南英 | 一种冬虫夏草真菌发酵液酵素及其制备方法 |
| CN104489846A (zh) * | 2014-12-02 | 2015-04-08 | 东莞市荷花食品有限公司 | 一种绞股蓝固体饮料及其制备方法 |
| CN105853507A (zh) * | 2016-05-09 | 2016-08-17 | 张钊 | 含绞股蓝的具有防治三高及护肝功效的保健药物组合物 |
-
2019
- 2019-07-02 CN CN201910591991.8A patent/CN110279112A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104041809A (zh) * | 2014-06-11 | 2014-09-17 | 沈南英 | 一种冬虫夏草真菌发酵液酵素及其制备方法 |
| CN104489846A (zh) * | 2014-12-02 | 2015-04-08 | 东莞市荷花食品有限公司 | 一种绞股蓝固体饮料及其制备方法 |
| CN105853507A (zh) * | 2016-05-09 | 2016-08-17 | 张钊 | 含绞股蓝的具有防治三高及护肝功效的保健药物组合物 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101544532B1 (ko) | 백수오 추출물을 포함하는 여성 갱년기 질환의 예방 또는 치료용 조성물 | |
| KR100795976B1 (ko) | 한약재 추출물을 유효성분으로 함유하는 당뇨병 예방 또는치료용 약학 조성물 | |
| KR101751398B1 (ko) | 당귀, 산수유, 녹용, 홍삼, 숙지황, 침향 및 벌꿀을 포함하는 항염증 조성물 | |
| KR101128564B1 (ko) | 생숙조화(生熟調和) 발효식초로 산도를 조절한 지초비누의 제조방법 | |
| KR20210112570A (ko) | 항 전염성 위장염 바이러스(tgev)용 조성물 및 이를 포함하는 약학 조성물 | |
| KR20130121324A (ko) | 차즈기 잎 추출물을 함유하는 숙취 예방 및 해소 조성물 | |
| CN112294708A (zh) | 一种弱酸性洗发护发活性洗剂 | |
| CN105148133B (zh) | 一种治四高中药茶 | |
| CN104489846A (zh) | 一种绞股蓝固体饮料及其制备方法 | |
| CN103642627A (zh) | 一种甘草五味子山药山楂枸杞复合发酵中草药保健酒 | |
| CN110279112A (zh) | 一种预防三高的绞股蓝酵素及其制备方法 | |
| KR101093730B1 (ko) | 발계（Ｓｍｉｌａｘ ｃｈｉｎａ）추출물을 유효성분으로 포함하는 염증성 질환 치료 및 예방용 조성물 | |
| CN102150828B (zh) | 一种养肝护肝的无花果制剂 | |
| KR101108712B1 (ko) | 발효 생약 입욕제 조성물의 제조방법, 그 방법으로 제조된 발효 생약 입욕제 조성물, 및 그 발효 생약 입욕제 조성물을 사용하는 방법 | |
| KR20140118322A (ko) | 탈모 예방 및 개선용 조성물과 그 제조 방법 | |
| KR101566822B1 (ko) | 생약재 추출물을 함유하는 아토피 증상 개선 증진용 화장료조성물 | |
| KR20120086262A (ko) | 진피 추출물을 유효성분으로 포함하는 염증성 질환 치료 및 예방용 조성물 | |
| KR101968891B1 (ko) | 멀꿀 열매 추출물을 유효성분으로 포함하는 혈중알콜농도 저감 촉진용 조성물 | |
| KR102211523B1 (ko) | 건강식품용 환 및 그 제조방법 | |
| KR20230081343A (ko) | 천연 발효 추출물을 성분으로 하는 모발 및 두피 개선용 조성물 | |
| KR101513973B1 (ko) | 한약재 혼합물을 포함하는 천연 방부제 조성물 및 그 제조방법 | |
| KR101350222B1 (ko) | 동백나무 열매 추출물을 함유하는 숙취해소용 조성물 | |
| KR101167628B1 (ko) | 흑삼을 함유하는 치매 예방 또는 치료 및 인지기능 개선 조성물 | |
| KR101131719B1 (ko) | 백두옹 추출물을 유효성분으로 포함하는 염증성 질환 치료 및 예방용 조성물 | |
| CN111821325A (zh) | 光叶子花提取物的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190927 |
|
| RJ01 | Rejection of invention patent application after publication |